The ROS1ders Issue RFA for $75K ROS1+ Cancer Innovation Award
Astro Bug/10275278
Trending...
- The Power Of Online Reviews & Why They Matter
- THSYU Opens New Doors for Accredited Investors, Bridging the Gap Between Traditional Finance and the Digital Asset Frontier
- New Website for Solo Agers Over 50
Patient-founded nonprofit seeks to stimulate innovative research to improve outcomes for patients with ROS1+ cancers.
SACRAMENTO, Calif. - AstroBug -- The ROS1ders is pleased to issue their 2024 Request for Application (RFA) to study ROS1-positive (ROS1+) cancer. The RFA is open to investigators who hold a doctorate degree and a faculty appointment at an academic or non-profit research institution anywhere in the world.
"While oral targeted therapies are approved to treat ROS1+ cancer, the drugs don't work for everyone, and they eventually stop working. We are committed to investing in research to improve patient outcomes," says Janet Freeman-Daily, MS, Engr, co-founder and president of The ROS1ders.
The ROS1+ Cancer Innovation Award aims to fund high-risk, high-reward projects focused on ROS1+ cancers. The one-year $75,000 seed grant can be used for pre-clinical, translational, or clinical research.
"Seed grants allow for the generation of initial data to support larger research endeavors," said D. Ross Camidge, MD, PhD, Professor of Medicine/Oncology at the University of Colorado and a member of The ROS1ders Scientific Advisory Board. "While some seeds fail, others grow into mighty trees - they can be the seeds of real breakthroughs."
More on Astro Bug
The award program uses a two-step application process. The deadline for a letter of intent is May 3, 2024. Those invited to submit a full application must provide it by August 4, 2024. For more information, visit https://theros1ders.org/seed-grant-program.
About the ROS1ders
Founded by patients in 2015 and incorporated in 2019, The ROS1ders is the largest global group of patients and family members living with ROS1+ cancer. It seeks to improve outcomes for all ROS1+ cancers through community, education, and research. Membership in their private Facebook group exceeds 1200 people from over 30 countries. The nonprofit is internationally recognized in the oncology and patient advocacy communities as experts in their disease. Its resources include a medically-vetted website and collaboration with international ROS1+ clinicians, researchers and industry. Please visit theros1ders.org to learn more.
More on Astro Bug
About ROS1+ Cancer
"While oral targeted therapies are approved to treat ROS1+ cancer, the drugs don't work for everyone, and they eventually stop working. We are committed to investing in research to improve patient outcomes," says Janet Freeman-Daily, MS, Engr, co-founder and president of The ROS1ders.
The ROS1+ Cancer Innovation Award aims to fund high-risk, high-reward projects focused on ROS1+ cancers. The one-year $75,000 seed grant can be used for pre-clinical, translational, or clinical research.
"Seed grants allow for the generation of initial data to support larger research endeavors," said D. Ross Camidge, MD, PhD, Professor of Medicine/Oncology at the University of Colorado and a member of The ROS1ders Scientific Advisory Board. "While some seeds fail, others grow into mighty trees - they can be the seeds of real breakthroughs."
More on Astro Bug
- Kelvin Emtech and Colm Engineering Unveil Strategic Joint Venture, to Boost Data Center and Building M&E Capabilities
- Bougie Dogwear Brings Handmade Luxury to Pet Fashion, One Stylish Accessory at a Time
- PetVet Medic First Aid Kits: The Ultimate Solution for Pet Emergencies Now Available
- Citizens for West Virginia Election Integrity Calls for Urgent Reforms to Safeguard State Elections
- Patton Launches SFP-based RS-232/422/485 Serial Device Server
The award program uses a two-step application process. The deadline for a letter of intent is May 3, 2024. Those invited to submit a full application must provide it by August 4, 2024. For more information, visit https://theros1ders.org/seed-grant-program.
About the ROS1ders
Founded by patients in 2015 and incorporated in 2019, The ROS1ders is the largest global group of patients and family members living with ROS1+ cancer. It seeks to improve outcomes for all ROS1+ cancers through community, education, and research. Membership in their private Facebook group exceeds 1200 people from over 30 countries. The nonprofit is internationally recognized in the oncology and patient advocacy communities as experts in their disease. Its resources include a medically-vetted website and collaboration with international ROS1+ clinicians, researchers and industry. Please visit theros1ders.org to learn more.
More on Astro Bug
- Local Tech Entrepreneur Partners with WonderSouq To Offer Downtown Medford Businesses a Virtual City Experience
- Boston Bridal Atelier Enhances Luxury Experience with New Bridal Shop Location
- New Website for Solo Agers Over 50
- Malcolm-Jamal Warner Returns to Columbia for an Unforgettable Evening of Poetry & Music
- Slightly Stoopid, Damian & Stephen Marley to headline Everwild Music Festival in 2025
About ROS1+ Cancer
- ROS1+ cancer is relatively rare, occurring in just 1-2% of non-small cell lung cancer (NSCLC). The incidence is thought to be similar in other types of cancer.
- Biomarker testing for ROS1 fusions is recommended in guidelines for non-small cell lung cancer (NSCLC), but for few other cancers.
- Patients are typically younger than the average NSCLC patient, have adenocarcinoma, and have no smoking history (a smoking history should not exclude patients from biomarker testing or targeted therapies).
- Oral targeted therapies are the recommended first-line treatment for metastatic ROS1+NSCLC and have increased the survival of patients by years. However, these drugs eventually stop working due to acquired resistance. The mechanisms of resistance are not well understood.
Source: The ROS1ders, Inc.
0 Comments
Latest on Astro Bug
- The One Experience™, Inc. Announces Presenting Sponsors and Partners for Flagship Event
- Introducing HOME-OMETRY, the Social Media Network for Real Estate
- Italian iGaming Landscape Expands with Notable Merger: Gaming Report Acquires Gaming Insider
- Retrospec Appoints Nick Marvik as New Head of Growth to Lead eCommerce Expansion
- $27 Million Funding; Coverage on Sanjay Gupta/CNN for Treatment of Suicidal Depression; Nasdaq Tier Uplisting: NRx Pharmaceuticals: Stock Symbol: NRXP
- Advanced HDR by Technicolor Enables 2024 UEFA Championship's French Broadcast in High Dynamic Range
- ®Grammy Award Winner Alex Cuba releases new single "El Día Más Triste"
- Performentor, LLC Announces 2025 Unleash People Energy® Award Winners
- LAIIER Closes Oversubscribed US$4M Seed Extension Funding Round, Led by Closed Loop Partners
- Deep Learning Robotics (DLRob) Secures European Patent Office Approval for Revolutionary Robot Learning Technology
- Turbocharge Small- and Medium-Size Business Financing with Faster Funding's Innovative Business Credit Building and Financing Suite
- Inframark's Oklahoma City Team Wins OWEA Awards, Exemplary Employer Accolade
- Hitachi Construction Machinery estabelece sede regional na América Latina no Chile
- Hitachi Construction Machinery establece su sede regional para América Latina en Chile
- Hitachi Construction Machinery Establishing Latin American Regional Headquarters in Chile
- New Book Further Unravels the Myth of a "Chemical Imbalance" Causing Depression
- Master P Launches Fishbone Express: A New Seafood Sensation
- FBI Agents in Operation Bullpen Allegedly Used Patriot Act to Spy on Fraud Suspects, Including Stan Fitzgerald -VFAF
- MEDIA ADVISORY: Leaders Across Georgia Gather in Atlanta for Georgia Municipal Association's Cities United Summit
- Enter the Dragon - PermianMuseum.com adds a Winged Dragon Fossil